Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors

两种 HER-2 B 细胞表位疫苗在实体瘤患者中的 I 期试验

• 批准号: 7737662
• 负责人: Tanios Bekaii-Saab
• 金额: $ 33万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-08-25 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7737662
• 关键词: Accounting; Active Immunotherapy; Adjuvant; Adrenal Glands; Affinity; Animals; Antibodies; Antitumor Response; Arts; Autoimmune Diseases; B-Lymphocyte Epitopes; B-Lymphocytes; Biological; Breast; Breast Cancer Cell; Cancer Control; Cancer Patient; Cardiotoxicity; Cessation of life; Cetuximab; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Colon; Colorectal Cancer; Combined Vaccines; Complex; Correlative Study; Data; Development; Disease; Disease Progression; Disseminated Malignant Neoplasm; Dose; Endometrial; Engineering; Epidermal Growth Factor Receptor; Epitopes; Erlotinib; Esophageal; FDA approved; Family; Frequencies; Funding; Generations; Goals; Growth; Human; Human Engineering; IgG1; Immune response; Immune system; Immunization; Immunologic Memory; Immunologic Monitoring; Immunotherapeutic agent; In Vitro; Individual; Intervention; Knowledge; Laboratories; Malignant Neoplasms; Malignant neoplasm of esophagus; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Mediating; Modeling; Neoplasm Metastasis; Non-Small-Cell Lung Carcinoma; Ovarian; Ovarian Squamous Cell Carcinoma; Passive Immunotherapy; Pathway interactions; Patient Care; Patients; Peptide Vaccines; Peptides; Pertuzumab; Phase; Phase I Clinical Trials; Phosphorylation; Physicians; Play; Production; Progressive Disease; Protein Tyrosine Kinase; Public Health; Radiation therapy; Radiosurgery; Receptor Signaling; Research; Resistance development; Risk; Roche brand of trastuzumab; Role; Safety; Science; Scientific Advances and Accomplishments; Scientist; Secondary Immunization; Series; Serious Adverse Event; Solid Neoplasm; Stable Disease; Stomach; Structure; T-Lymphocyte; T-Lymphocyte Epitopes; Testing; Therapeutic; Toxic effect; Training; Transgenic Mice; Trastuzumab; Tumor Antigens; Tyrosine Kinase Domain; Vaccination; Vaccines; Vascular Endothelial Growth Factor Receptor; Vascular Endothelial Growth Factors; Work; antibody-dependent cell cytotoxicity; base; bevacizumab; cancer therapy; cancer type; chemotherapy; clinical application; cost; design; hormone therapy; immunogenicity; in vitro activity; in vivo; inhibitor/antagonist; killings; lapatinib; malignant breast neoplasm; neoplastic cell; partial response; pre-clinical; preclinical study; prevent; programs; public health relevance; receptor; response; small molecule; stem; synthetic peptide; three dimensional structure; tumor; tumor growth; vaccine candidate

DESCRIPTION (provided by applicant): The human immune system is a potentially powerful line of defense against cancer. Many biological obstacles exist in cancer patients that can thwart tumor specific immune responses. While there is compelling evidence that the immune system is capable of generating highly effective antitumor responses, the vast majority of immunotherapeutic interventions show only modest clinical impact. The opportunity to train the immune system to efficiently recognize and kill tumor cells could be highly significant because of the generation of immunologic memory induced by vaccination. The hypothesis in this application is that the design of unique B cell epitope peptides which can recapitulate the exquisite native structure of the tumor antigen and when combined with a "promiscuous" T cell activating species results in the production of highly efficacious native-like antipeptide antibodies. We have demonstrated in preclinical studies that such endogenous antibodies can delay, prevent and/or eradicate tumor growth and metastasis with increased efficacy and little or no toxicity. Thus, the overall goal of this project is to continue to test this hypothesis in humans by attempting to control or cure metastatic cancers. Human epidermal growth factor receptor (HER) signaling inhibition plays a major role in targeted cancer therapies. HER-2 over expression and amplification is seen in subsets of breast, gastric, esophageal, endometrial, uterine, ovarian, and lung cancers. HER-2 plays a major coordinating role in this network of family of HER receptors (EGFR (HER-1), HER-2, HER-3, and HER-4). To achieve our objectives two aims are proposed: Specific Aim 1: To perform early phase clinical trial assessing safety and clinical toxicity of immunization, as well as to establish an optimum biologically dose (OBD) of combination vaccines. Specific Aim 2: To determine whether both humoral and cellular immune responses are elicited in patients immunized with combination vaccines and nor-MDP as adjuvant and to study the underlying mechanisms of anti-tumor activity in vitro and in vivo. Correlative studies that include state of the art immunological monitoring, in vitro mechanism of action. In this project basic and clinical science will be conducted in parallel, each informing the other; basic scientists and physician-scientists will work together as a team to develop discovery-based science that will change the care of patients. PUBLIC HEALTH RELEVANCE: The proposed clinical trial and research program has as its goal to define the basic knowledge required for engineering the human immune system to recognize and destroy deadly forms of cancer. Both preclinical animal and human clinical studies with a HER-2 peptide vaccine point to the possibility of controlling cancer. This project will be to continue to determine whether better peptide vaccines can be engineered to produce cancer-killing antibodies with high efficacy. Scientific advances from this project will have a significant public health impact for cancer. The advantage of active immunotherapy with safe and non toxic natural synthetic peptides over passive immunotherapy with mAbs such as trastuzumab (Herceptin) is a fundamental aspect of this work.

描述（由申请人提供）：人类免疫系统是针对癌症的潜在强大防御线。癌症患者存在许多生物障碍，可以阻止肿瘤特异性免疫反应。尽管有令人信服的证据表明免疫系统能够产生高效的抗肿瘤反应，但绝大多数免疫治疗干预措施仅显示出适度的临床影响。训练免疫系统有效识别和杀死肿瘤细胞的机会可能非常重要，因为疫苗接种引起的免疫记忆产生。该应用中的假设是，独特的B细胞表位肽的设计可以概括肿瘤抗原的精致天然结构，并且与“混杂” T细胞激活物种结合时会导致产生高效的天然样本样抗肽抗体。我们在临床前研究中证明，这种内源性抗体可以延迟，预防和/或消除肿瘤的生长和转移，而有效性增加，毒性很小或毒性很小。因此，该项目的总体目标是通过试图控制或治愈转移性癌症来继续检验人类中的这一假设。人表皮生长因子受体（她）信号抑制在靶向癌症疗法中起主要作用。 HER-2在乳房，胃，食管，子宫内膜，子宫，卵巢癌和肺癌的子集中可以看到HER-2。 HER-2在她的受体家庭（EGFR（HER-1），HER-2，HER-3和HER-4）中扮演着重要的协调角色。为了实现我们的目标，提出了两个目标：具体目标1：进行早期临床试验，评估免疫的安全性和临床毒性，以及建立组合疫苗的最佳生物学剂量（OBD）。具体目的2：确定用组合疫苗和NOR-MDP作为辅助的患者引起体液和细胞免疫反应，并研究体外和体内抗肿瘤活性的潜在机制。相关研究，包括最先进的免疫监测，体外作用机理。在这个项目中，基础科学和临床科学将平行进行，每个科学都通知彼此；基础科学家和医师科学家将作为一个团队共同努力，开发基于发现的科学，以改变患者的护理。公共卫生相关性：拟议的临床试验和研究计划的目标是定义工程人类免疫系统所需的基本知识，以识别和破坏致命的癌症形式。 Her-2肽疫苗的临床前动物和人类临床研究都表明控制癌症的可能性。该项目将继续确定是否可以设计更好的肽疫苗以产生具有高疗效的癌症抗体。该项目的科学进步将对癌症产生重大的公共卫生影响。具有安全和非毒性天然合成肽的主动免疫疗法的优势比用曲妥珠单抗（Herceptin）等MAB的被动免疫疗法的优势是这项工作的基本方面。